- Home
- MBRX vs BRTX Comparison
MBRX vs BRTX Comparison
Compare MBRX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBRX | BRTX |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.3M |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBRX | BRTX |
|---|---|---|
| Price | $2.23 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | 112.9K | ★ 3.5M |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $438.78 |
| Revenue Next Year | N/A | $61.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $0.19 |
| 52 Week High | $7.98 | $2.04 |
Technical Indicators
Market Signals| Indicator | MBRX | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.18 | 41.06 |
| Support Level | $0.37 | $0.20 |
| Resistance Level | $5.15 | $0.31 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 45.45 | 54.65 |
Price Performance
Historical ComparisonAbout MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.